Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Exicure Yönetim

Yönetim kriter kontrolleri 0/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Paul Kang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.2yrs
Yönetim Kurulu ortalama görev süresi	1.2yrs

Son yönetim güncellemeleri

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

CEO

Paul Kang (62 yo)

1.2yrs

Görev süresi

Mr. Paul Kang is Director of Exicure, Inc. from February 24, 2023 and serves as its Chief Executive Officer since August 21, 2023 and has been its President. He is associated with CBI USA Inc. Mr. Kang beg...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Paul Kang	CEO, President & Director	1.2yrs	Veri yok	Veri yok
Jiyoung Hwang	CFO, Secretary & Director	1.2yrs	Veri yok	Veri yok
Joshua Miller	Chief Accounting Officer	1.4yrs	Veri yok	0.012% $ 725.3

1.2yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: XCUR's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Paul Kang	CEO, President & Director	1.7yrs	Veri yok	Veri yok
Jiyoung Hwang	CFO, Secretary & Director	1.7yrs	Veri yok	Veri yok
Michael Hodges	Member of Advisory Board	no data	Veri yok	Veri yok
Amy Paller	Member of Advisory Board	no data	Veri yok	Veri yok
Henry Paulson	Member of Advisory Board	4.8yrs	Veri yok	Veri yok
Hojoon Lee	Director	1.2yrs	Veri yok	Veri yok
Hyuk Ko	Independent Director	1.2yrs	Veri yok	Veri yok
Dongho Lee	Independent Director	1.2yrs	Veri yok	Veri yok
Minhee Eom	Independent Director	1.1yrs	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: XCUR's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Exicure Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure, Inc., Annual General Meeting, Jun 28, 2024

No independent directors

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure, Inc. Announces Executive Changes

Recent updates

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure regains compliance with Nasdaq's minimum bid price requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Price target decreased to US$6.75

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$12.9m

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Consensus revenue estimates increase to US$22.1m

Price target decreased to US$9.00

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Consensus revenue estimates fall to US$5.77m

Price target decreased to US$9.60

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Consensus revenue estimates increase to US$8.91m

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election

Exicure Announces Appointments of Board of Directors

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

New 90-day high: US$2.80

Exicure Appoints James Sulat to Board of Directors